Stockscreener 앱 받기
322.30
0.56%
1.64
전일 마감가:
$320.66
열려 있는:
$317.25
하루 거래량:
701.34K
Relative Volume:
0.47
시가총액:
$42.78B
수익:
$3.71B
순이익/손실:
$313.75M
주가수익비율:
142.79
EPS:
2.2571
순현금흐름:
$465.38M
1주 성능:
-0.80%
1개월 성능:
+0.77%
6개월 성능:
-33.12%
1년 성능:
+31.87%
1일 변동 폭
$313.12
$323.46
1주일 범위
$312.09
$328.28
52주 변동 폭
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
322.58 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.19 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.20 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
735.96 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ONC
Beone Medicines Ltd Adr
|
301.97 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-07 | 재개 | Oppenheimer | Outperform |
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Partnership With Tenaya Therapeutics - simplywall.st
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness - Yahoo Finance
ALNYLAM PHARMACEUTICALS Executives Sell Shares - TradingView
Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After Recent Share Price Pullback - simplywall.st
Victory Capital Management Inc. Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal - Pharmaceutical Technology
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs - Yahoo Finance
Alnylam Updates Hypertension Pipeline And AMVUTTRA Access Shape Valuation View - Sahm
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Responsive Playbooks and the ALNY Inflection - Stock Traders Daily
Tenaya To Evaluate Genetic Cardiovascular Targets For Alnylam - Citeline News & Insights
Alnylam board creates $18M incentive award to keep CEO through 2029 - The Business Journals
Tenaya Therapeutics Stock Jumps After New Alnylam Deal - Benzinga
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - BioWorld MedTech
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics - Investing News Network
Tenaya wins support from Alnylam in cardio disease pact - Endpoints News
Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments - marketscreener.com
Tenaya Therapeutics Signs Potential $1.13 Billion Deal With Alnylam - marketscreener.com
Alnylam Pharmaceuticals (ALNY) Forms Partnership for Cardiovascu - GuruFocus
Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development - PR Newswire
Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration - TipRanks
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - Seeking Alpha
Tenaya Therapeutics enters into research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapeutics - marketscreener.com
Tenaya Therapeutics Enters into Research Collaboration with - GlobeNewswire
Focus Partners Advisor Solutions LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
CI Investments Inc. Buys 3,109 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Canada’s AMVUTTRA Reimbursement Tailwind Altering The Investment Case For Alnylam Pharmaceuticals (ALNY)? - Yahoo Finance
Alnylam Grants CEO New Performance-Based Equity Award - The Globe and Mail
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Sells 6,799 Shares of Stock - MarketBeat
Alnylam CEO Greenstreet sells $2.23 million in stock - Investing.com India
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $523,584.70 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Pushkal Garg Sells 1,717 Shares - MarketBeat
Alnylam (NASDAQ: ALNY) EVP receives new options and RSUs - Stock Titan
Alnylam Reimbursement Win And Trial Progress Versus Current Valuation Signals - Yahoo Finance
Alnylam Pharmaceuticals grants performance-based equity award to CEO By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals grants performance-based equity award to CEO - Investing.com Nigeria
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Presents a Growth Story at a Technical Turning Point - ChartMill
Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors - BioSpace
Pushkal Garg (ALNY) reports sale of 4,627 shares for $1.53M - Stock Titan
The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following AMVUTTRA Uptake And Canada Reimbursement News - simplywall.st
Rafferty Asset Management LLC Sells 15,045 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Elo Mutual Pension Insurance Co Purchases 3,738 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals Touts AMVUTTRA Momentum, Teases Key Pipeline Readouts at TD Cowen Conf. - Yahoo Finance
ALNY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Alnylam (NASDAQ: ALNY) CEO converts 5,921 RSUs into common stock - Stock Titan
Alnylam (ALNY) CFO receives 1,908 shares as final RSU tranche vests - Stock Titan
Alnylam (ALNY) CCO receives 1,666 shares from RSU vesting - Stock Titan
Alnylam (NASDAQ: ALNY) R&D chief sells 4,627 shares under plan - Stock Titan
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: An 84.90% Revenue Surge and 37.27% Upside Potential - DirectorsTalk Interviews
Paroxysmal Nocturnal Hemoglobinuria Market: Expanding Revenue Landscape to 2034 – DelveInsight | Alexion Pharma, Hoffmann-La Roche, Novartis, Regeneron Pharma, AKARI Therapeutics, AstraZeneca - Barchart.com
Alnylam Pharmaceuticals receives positive recommendation from Canada's drug agency for public reimbursement of Amvuttra - marketscreener.com
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alnylam Pharmaceuticals Inc 주식 (ALNY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Garg Pushkal | EVP Chief R&D |
Mar 04 '26 |
Sale |
323.08 |
2,309 |
745,984 |
21,097 |
| Greenstreet Yvonne | Chief Executive Officer |
Mar 04 '26 |
Sale |
323.08 |
2,933 |
947,581 |
95,695 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Mar 04 '26 |
Sale |
323.08 |
2,468 |
797,351 |
61,805 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Mar 04 '26 |
Sale |
323.08 |
2,309 |
745,984 |
34,297 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 05 '26 |
Sale |
323.98 |
658 |
213,177 |
20,569 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Mar 04 '26 |
Sale |
323.08 |
633 |
204,508 |
21,227 |
1.06%
0.36%
자본화:
|
볼륨(24시간):